Attending EASL 2026?
Get our free prep guide: key sessions by day, satellite symposia listings, and recommended spots near the venue.
Free. No spam. Unsubscribe anytime.
Official Registration
Visit Official Website ↗Strategic Context
EASL Congress is Europe’s largest event dedicated to liver health, bringing together professionals and partners to share knowledge, highlight breakthroughs, and build meaningful connections. Participants will engage with a comprehensive scientific programme spanning the full spectrum of hepatology, fostering cross-border collaboration and dialogue.
Who Attends
Doctors, Scientists, Allied Health Professionals, Patients, Industry Partners, Hepatology Research Community
Coverage from EASL 2026
EASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
EASL 2026 data indicates non-invasive markers may reduce liver biopsy necessity for MASH diagnosis, offering a less burdensome alternative.
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Despite 2024 EASL guidelines for MASLD, physicians encounter significant barriers in screening and diagnosis, particularly in SEEMEA.
EASL 2026: PSC Therapies Advance Beyond Symptom Management
EASL 2026 discussions highlighted progress in primary sclerosing cholangitis (PSC) treatment, moving from symptom control to disease modification.
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
New A-TANGO organ failure score refines acute-on-chronic liver failure (ACLF) diagnosis and prognostication in hospitalised cirrhosis patients.
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
Experts at EASL 2026 discussed the distinct challenges of managing advanced fibrosis in MASH, highlighting diagnostic and therapeutic complexities.
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
Late-onset genetic cholestatic diseases are frequently missed in adults, leading to delayed diagnosis and suboptimal management. Increased awareness is critical.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
EASL 2026: Alcohol Policy Action Needed for Liver Disease
The European Health Alliance on Alcohol advocates for policy changes to mitigate alcohol-related liver disease, emphasizing the gap between clinical evidence and public health action.
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
EASL 2026 discussions reaffirmed peginterferon alfa as the cornerstone of HDV management, with emerging therapies showing promise.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
A new consensus statement from EASL 2026 aims to standardise the diagnosis and management of Alpha-1 Antitrypsin Deficiency (AATD) related liver disease.
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
EASL 2026 highlights the evolving role of non-invasive diagnostics in liver disease, offering improved accuracy for fibrosis and steatosis assessment.
